NetworkNewsBreaks – Clene Inc.’s (NASDAQ: CLNN
Post# of 154
(Total Views: 104)
Posted On: 03/19/2024 4:53:45 PM
NetworkNewsBreaks – Clene Inc.’s (NASDAQ: CLNN) Work in Nanotechnology Highlighted in ‘First in Human’ Podcast
Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company, was featured in a recent episode of First in Human, a biotech-focused podcast featuring interviews with industry leaders and investors to learn about their journeys to in-human clinical trials. Hosted by Vial EVP Rich McCormick, the podcast is available for on-demand listening on First in Human by Vial. Rob Etherington, president, director and CEO of Clene joined the program to highlight information about the company’s work in the field of nanotechnology. “For decades…the idea of a therapeutic elemental metal having some medicinal efficacy has been well understood. We at Clene had the idea to combine this with the mechanism of a nanotherapeutic, providing, at the atomic level, the ability to drive energy into the failing mitochondria that powers your and my brain,” Etherington said during the interview.
“We first completed some translational medicine work, whereby we were able to show that our drug taken orally got into the stomach then into the bloodstream and then across the blood brain barrier to drive the key bio energetic metabolites that you and I rely upon for energy… we were able to reverse the clock potentially by decades, in terms of key bioenergetic metabolites. We then proceeded into two amyotrophic lateral sclerosis (‘ALS’) studies and one multiple sclerosis study, all of which have concluded in the past 18 months. These studies have shown the ability of CNM-Au8(R) to improve function, which can be translated as how to improve the way patients move and walk and talk and eat and chew and breathe.”
NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://nnw.fm/CLNN
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company, was featured in a recent episode of First in Human, a biotech-focused podcast featuring interviews with industry leaders and investors to learn about their journeys to in-human clinical trials. Hosted by Vial EVP Rich McCormick, the podcast is available for on-demand listening on First in Human by Vial. Rob Etherington, president, director and CEO of Clene joined the program to highlight information about the company’s work in the field of nanotechnology. “For decades…the idea of a therapeutic elemental metal having some medicinal efficacy has been well understood. We at Clene had the idea to combine this with the mechanism of a nanotherapeutic, providing, at the atomic level, the ability to drive energy into the failing mitochondria that powers your and my brain,” Etherington said during the interview.
“We first completed some translational medicine work, whereby we were able to show that our drug taken orally got into the stomach then into the bloodstream and then across the blood brain barrier to drive the key bio energetic metabolites that you and I rely upon for energy… we were able to reverse the clock potentially by decades, in terms of key bioenergetic metabolites. We then proceeded into two amyotrophic lateral sclerosis (‘ALS’) studies and one multiple sclerosis study, all of which have concluded in the past 18 months. These studies have shown the ability of CNM-Au8(R) to improve function, which can be translated as how to improve the way patients move and walk and talk and eat and chew and breathe.”
NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://nnw.fm/CLNN
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)